CIK 0001438533
- Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- Operating
- EIN
- 262383102
- Phone
- +1 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,495,607
- in 10 filings, $79.5M under 10b5-1 plans
Net −$79,495,607. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 20 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-10 | REED ELIZABETH E SVP, GC & CORPORATE SECRETARY | Exercise or conversion · Performance-based restricted stock units 10b5-1 | −8,000 | 0 | ||
| 2025-02-10 | Heerma Peter CHIEF COMMERCIAL OFFICER | Exercise or conversion 10b5-1 | +8,000 | 130,708 | ||
| 2025-02-10 | Heerma Peter CHIEF COMMERCIAL OFFICER | Exercise or conversion · Performance-based restricted stock units 10b5-1 | −8,000 | 0 | ||
| 2025-02-10 | Inrig Jula CHIEF MEDICAL OFFICER | Exercise or conversion | +8,000 | 92,170 | ||
| 2025-02-10 | Inrig Jula CHIEF MEDICAL OFFICER | Exercise or conversion · Performance-based restricted stock units | −8,000 | 0 | ||
| 2025-02-06 | Baynes Roy D. Director | Exercise or conversion 10b5-1 | +10,000 | $17.44 | $174K | 41,000 |
| 2025-02-06 | Baynes Roy D. Director | Sale 10b5-1 | −10,000 | $22.00 | $220K | 31,000 |
| 2025-02-06 | Baynes Roy D. Director | Exercise or conversion · Stock option (right to buy) 10b5-1 | −10,000 | 0 | ||
| 2025-02-04 | Inrig Jula CHIEF MEDICAL OFFICER | Sale 10b5-1 | −1,066 | $20.11 | $21K | 84,170 |
| 2025-02-03 | ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&D | Sale 10b5-1 | −8,951 | $19.78 | $177K | 95,719 |
| 2025-02-03 | REED ELIZABETH E SVP, GC & CORPORATE SECRETARY | Sale 10b5-1 | −8,951 | $19.78 | $177K | 89,482 |
| 2025-02-03 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −50,691 | $20.21 | $1.0M | 430,548 |
| 2025-02-03 | Inrig Jula CHIEF MEDICAL OFFICER | Sale 10b5-1 | −4,207 | $20.12 | $85K | 85,236 |
| 2025-02-03 | Heerma Peter CHIEF COMMERCIAL OFFICER | Sale | −5,166 | $20.12 | $104K | 122,708 |
| 2025-02-03 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale | −5,192 | $20.12 | $104K | 90,038 |
| 2025-02-03 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Sale | −3,348 | $20.12 | $67K | 63,654 |
| 2025-01-31 | ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&D | Grant or award 10b5-1 | +21,500 | 104,670 | ||
| 2025-01-31 | ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&D | Grant or award · Employee stock option (right to buy) 10b5-1 | +58,000 | 58,000 | ||
| 2025-01-31 | REED ELIZABETH E SVP, GC & CORPORATE SECRETARY | Grant or award 10b5-1 | +21,500 | 98,433 | ||
| 2025-01-31 | REED ELIZABETH E SVP, GC & CORPORATE SECRETARY | Grant or award · Employee stock option (right to buy) 10b5-1 | +58,000 | 58,000 |
Page 20 of 59 · 1,174 trades